ATE373239T1 - Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs - Google Patents

Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs

Info

Publication number
ATE373239T1
ATE373239T1 AT04714080T AT04714080T ATE373239T1 AT E373239 T1 ATE373239 T1 AT E373239T1 AT 04714080 T AT04714080 T AT 04714080T AT 04714080 T AT04714080 T AT 04714080T AT E373239 T1 ATE373239 T1 AT E373239T1
Authority
AT
Austria
Prior art keywords
mif
prostate cancer
inhibitory factor
macrophage migration
migration inhibitory
Prior art date
Application number
AT04714080T
Other languages
English (en)
Inventor
Katherine Siegler
Original Assignee
Us Dept Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Dept Veterans Affairs filed Critical Us Dept Veterans Affairs
Application granted granted Critical
Publication of ATE373239T1 publication Critical patent/ATE373239T1/de

Links

Classifications

    • G01N33/57555—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04714080T 2003-02-24 2004-02-24 Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs ATE373239T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44889403P 2003-02-24 2003-02-24
US10/644,797 US7361474B2 (en) 2003-02-24 2003-12-17 Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer

Publications (1)

Publication Number Publication Date
ATE373239T1 true ATE373239T1 (de) 2007-09-15

Family

ID=32912312

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04714080T ATE373239T1 (de) 2003-02-24 2004-02-24 Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs

Country Status (7)

Country Link
US (1) US7361474B2 (de)
EP (1) EP1601968B1 (de)
AT (1) ATE373239T1 (de)
AU (1) AU2004214971A1 (de)
CA (1) CA2517076A1 (de)
DE (1) DE602004008889T2 (de)
WO (1) WO2004076679A2 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US7897349B2 (en) * 2003-12-30 2011-03-01 The United States Of America As Represented By The Department Of Veterans Affairs Macrophage migration inhibitory factor (MIF) as marker for urological inflammatory disease
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
WO2006044946A2 (en) * 2004-10-20 2006-04-27 Onco Detectors International, Llc Migration inhibitory factor in serum as a tumor marker for prostate, bladder, breast, ovarian, kidney and lung cancer
US20060105405A1 (en) * 2004-10-20 2006-05-18 Onco Detectors International, Llc Migration inhibitory factor in serum as a tumor marker for prostate, bladder, breast, ovarian, kidney, pancreatic and lung cancer and for diagnosis of endometriosis
CA2600175A1 (en) 2005-03-24 2006-03-20 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
US7745121B2 (en) * 2005-05-23 2010-06-29 The Department Of Veterans Affairs Polymorphism in the macrophage migration inhibitory factor (MIF) gene as marker for prostate cancer
WO2007044566A2 (en) * 2005-10-07 2007-04-19 Baylor Research Institute Diagnosis of systemic onset juvenile idiopathic arthritis through blood leukocyte microarray analysis
EP2363205A3 (de) 2006-01-11 2014-06-04 Raindance Technologies, Inc. Mikrofluidische Vorrichtungen Und Verfahren Zur Verwendung Bei Der Bildung Und Kontrolle Von Nanoreaktoren
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP3782722B1 (de) 2006-05-11 2022-07-06 Bio-Rad Laboratories, Inc. Mikrofluidische vorrichtungen
EP3536396B1 (de) 2006-08-07 2022-03-30 The President and Fellows of Harvard College Fluorkohlenstoffemulsionsstabilisierende tenside
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
US8252529B2 (en) * 2008-06-12 2012-08-28 The Invention Science Fund I, Llc Methods for collecting and detecting oligonucleotides
US8252528B2 (en) * 2008-06-12 2012-08-28 The Invention Science Fund I, Llc Methods, compositions, and kits for collecting and detecting oligonucleotides
US8614057B2 (en) * 2008-06-12 2013-12-24 The Invention Science Fund I, Llc Methods for collecting and detecting oligonucleotides
US20110176325A1 (en) * 2008-07-10 2011-07-21 3M Innovative Properties Company Viscoelastic lightguide
JP5681104B2 (ja) 2008-07-10 2015-03-04 スリーエム イノベイティブ プロパティズ カンパニー 粘弾性導光体を有する再帰反射物品及びデバイス
TW201007647A (en) * 2008-07-10 2010-02-16 3M Innovative Properties Co Retroreflective articles and devices having viscoelastic lightguide
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
WO2010009365A1 (en) 2008-07-18 2010-01-21 Raindance Technologies, Inc. Droplet libraries
WO2010017087A1 (en) * 2008-08-08 2010-02-11 3M Innovative Properties Company Lightguide having a viscoelastic layer for managing light
DE102008063046A1 (de) 2008-12-23 2010-06-24 Justus-Liebig-Universität Giessen Medizinische Verwendung des ribosomalen Protein S19 (RPS19)
EP3415235B1 (de) 2009-03-23 2025-11-12 Bio-Rad Laboratories, Inc. Manipulation von mikrofluidiktröpfchen
JP5671003B2 (ja) 2009-04-15 2015-02-18 スリーエム イノベイティブ プロパティズ カンパニー ナノ中空物品用プロセス及び装置
US9464179B2 (en) 2009-04-15 2016-10-11 3M Innovative Properties Company Process and apparatus for a nanovoided article
EP2419767A1 (de) 2009-04-15 2012-02-22 3M Innovative Properties Company Optischer film
EP2445541A1 (de) 2009-06-25 2012-05-02 3M Innovative Properties Company Lichtaktivierter antimikrobieller artikel und verfahren zu seiner verwendung
EP2448603A1 (de) 2009-06-30 2012-05-09 3M Innovative Properties Company Lichtaktivierter antimikrobieller artikel und verfahren zu seiner verwendung
JP5706419B2 (ja) 2009-08-21 2015-04-22 スリーエム イノベイティブ プロパティズ カンパニー 組織照明用の方法及び製品
WO2011022023A1 (en) 2009-08-21 2011-02-24 3M Innovative Properties Company Methods and products for reducing tissue trauma using water-absorbing stress-distributing materials
CN102625678B (zh) 2009-08-21 2016-01-20 3M创新有限公司 使用耐水性应力分布材料减小组织创伤的方法和产品
EP2486409A1 (de) 2009-10-09 2012-08-15 Universite De Strasbourg Markiertes nanomaterial auf siliziumbasis mit verbesserten eigenschaften und seine verwendung
WO2011079176A2 (en) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
KR20120123741A (ko) 2010-01-13 2012-11-09 쓰리엠 이노베이티브 프로퍼티즈 컴파니 미세 구조화 저 굴절률 나노공극형 층을 갖는 광학 필름 및 이의 제조 방법
EP2534509B1 (de) 2010-02-10 2019-07-24 3M Innovative Properties Company Beleuchtungsvorrichtung mit einer viskoelastischen schicht
JP5934657B2 (ja) 2010-02-12 2016-06-15 レインダンス テクノロジーズ， インコーポレイテッド デジタル検体分析
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
WO2012050663A1 (en) 2010-10-11 2012-04-19 3M Innovative Properties Company Illumination device having viscoelastic lightguide
JP6001545B2 (ja) 2010-10-20 2016-10-05 スリーエム イノベイティブ プロパティズ カンパニー ナノ空隙ポリマー層を組み込んだ広帯域半鏡面ミラーフィルム
US20130250614A1 (en) 2010-12-04 2013-09-26 3M Innovative Properties Company Illumination assembly and method of forming same
TW201232125A (en) 2010-12-04 2012-08-01 3M Innovative Properties Co Illumination assembly and method of forming same
EP3859011A1 (de) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Verfahren zur bildung gemischter tröpfchen
EP2675819B1 (de) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Zusammensetzungen und verfahren für molekulare etikettierung
KR101985030B1 (ko) 2011-05-25 2019-05-31 쓰리엠 이노베이티브 프로퍼티즈 컴파니 광 제어 필름
EP3216872B1 (de) 2011-06-02 2020-04-01 Bio-Rad Laboratories, Inc. Enzymquantifizierung
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
EP2823303A4 (de) 2012-02-10 2015-09-30 Raindance Technologies Inc Molekulardiagnostischer screeningtest
EP3524693A1 (de) 2012-04-30 2019-08-14 Raindance Technologies, Inc. Digitale analytanalyse
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
EP3090063B1 (de) 2013-12-31 2019-11-06 Bio-Rad Laboratories, Inc. Verfahren zur detektion von latentem retrovirus
US9904001B2 (en) 2014-03-18 2018-02-27 3M Innovative Properties Company Marketing strip with viscoelastic lightguide
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3789413T2 (de) * 1986-10-03 1994-07-28 Ciba Geigy Ag Lymphokin-ähnliche Peptide.
US5250297A (en) 1989-10-20 1993-10-05 Hybritech Incorporated Tumor-associated antigen, antibodies, compositions and uses therefor
US5614372A (en) 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
US5654161A (en) 1995-05-12 1997-08-05 Chiron Diagnostics Corporation Method for diagnosing prostate cancer
US6420188B1 (en) 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
US6043044A (en) 1997-07-15 2000-03-28 Hudson; Perry B. Macrophage migration inhibitory factor as diagnostic and prognostic marker for metastatic adenocarcinoma
US6268151B1 (en) 2000-01-20 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of macrophage migration inhibitory factor expression
US20030235584A1 (en) * 2000-02-28 2003-12-25 Kloetzer William S. Method for preparing anti-MIF antibodies

Also Published As

Publication number Publication date
CA2517076A1 (en) 2004-09-10
WO2004076679A3 (en) 2004-10-28
US20040171021A1 (en) 2004-09-02
EP1601968A2 (de) 2005-12-07
US7361474B2 (en) 2008-04-22
AU2004214971A1 (en) 2004-09-10
EP1601968B1 (de) 2007-09-12
DE602004008889T2 (de) 2008-06-12
WO2004076679A2 (en) 2004-09-10
DE602004008889D1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
ATE373239T1 (de) Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs
Liu et al. Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers
Janz et al. Y‐box factor YB‐1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI‐1
O'Brien et al. CENP‐F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer
Lee et al. Diagnostic significance of serum HMGB1 in colorectal carcinomas
Hlavata et al. The role of ABC transporters in progression and clinical outcome of colorectal cancer
Qi et al. SERPINH 1 overexpression in clear cell renal cell carcinoma: association with poor clinical outcome and its potential as a novel prognostic marker
Li et al. Keratin 80 promotes migration and invasion of colorectal carcinoma by interacting with PRKDC via activating the AKT pathway
Bai et al. High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients
Park et al. Serum CA 19–9, cathepsin D, and matrix metalloproteinase‐7 as a diagnostic panel for pancreatic ductal adenocarcinoma
Lee et al. High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients
ATE457362T1 (de) Mrna-verhältnisse in harnsedimenten und/oder harn als prognostische und/oder theranostische marker für prostatakrebs
JP2015505370A5 (de)
O'Brien et al. The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro
EP4045912A1 (de) Vorrichtungen und verfahren zum nachweis von bauchspeicheldrüsenkrebs
WO2006036788A3 (en) Methods and compositions for evaluating breast cancer prognosis
RU2011106957A (ru) Онкоген nrf2 и его применение
DE602006020544D1 (de) Apolipoprotein-a-ii-isoform als biomarker für prostatakrebs
JP2010535014A5 (de)
RU2008101660A (ru) Способ диагностики болезни альцгеймера
Maryáš et al. Proteomics in investigation of cancer metastasis: functional and clinical consequences and methodological challenges
Kuang et al. tRNA‐based prognostic score in predicting survival outcomes of lung adenocarcinomas
WO2014198995A1 (es) Biomarcadores para el diagnóstico y respuesta al tratamiento en cáncer de páncreas
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
Tang et al. Reduction of AZGP1 predicts poor prognosis in esophageal squamous cell carcinoma patients in Northern China

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties